Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Samir Parikh, MD, on the B-cell pathway in IgA nephropathy, biomarker gaps, treatment sequencing, and the case for earlier detection.

Understanding the B-Cell Pathway in IgA Nephropathy, With Samir Parikh, MD

Dana Rizk, MD, joins hosts Brendon Neuen and Shikha Wadhwani to unpack 2-year VISIONARY data showing sibeprenlimab stabilizes eGFR in IgAN.

Kidney Compass: VISIONARY 2-Year eGFR Data in IgA Nephropathy

Brad Rovin, MD, discusses persistent gaps in IgA nephropathy diagnosis and treatment, from RAS inhibition limits to the promise of B-cell-targeted therapies.

What's Still Missing in IgA Nephropathy Care, With Brad Rovin, MD

Brad Rovin, MD, discusses gaps in IgA nephropathy care, biopsy's expanding role, and how new B cell therapies are reshaping treatment.

Closing Gaps in IgA Nephropathy Diagnosis and Treatment, With Brad Rovin, MD

Sibeprenlimab (Voyxact) achieves KDIGO goal, stabilizing eGFR decline in IgA nephropathy at 2-year Phase 3 VISIONARY readout. 

Sibeprenlimab (Voyxact) Stabilizes Kidney Function in IgAN

Nephrology in July 2026: FDA approvals for atacicept, iptacopan, and Furoscix in IgAN/CKD, plus new IgAN and CKD trial data.

8 Nephrology Headlines You Missed in July 2026

Ramy Hanna, MD, discusses early IgAN recognition, biopsy decisions, and how emerging therapies are reshaping disease management.


Early Detection and Treatment Advances in IgA Nephropathy, With Ramy Hanna, MD

IgA nephropathy shows a male predominance, but researchers have not identified why. Ramy Hanna, MD explores possible biological explanations.


Why Does IgA Nephropathy Affect More Men? With Ramy Hanna, MD 

Richard Lafayette, MD, discusses how atacicept's FDA approval advances BAFF/APRIL targeting in IgA nephropathy.

Atacicept and Upstream Immune Targeting in IgAN With Richard Lafayette, MD

ORIGIN 3 investigator brings atacicept approval to BAFF/APRIL targeting to IgAN 

Atacicept Approval Brings BAFF/APRIL Targeting to IgAN With Richard Lafayette, MD

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.